With brand-name GLP-1s for obesity treatment on and off the shortage list, prescribing can get complicated. Five providers ...

Hims & Hers (NYSE:HIMS) has launched an online GLP-1 supply tracker where people can share information ... The FDA recently ...

In October, the FDA removed Mounjaro and Zepbound—the diabetes and obesity GLP-1 drugs made by Eli Lilly—from the shortage ...

Some GLP-1 receptor agonists may hold promise as treatments for alcohol use disorder (AUD), a Swedish observational study ...

Hims & Hers is launching a tracker of GLP-1 shortages to push back against the FDA's recent moves to end compounding copycats ...

As the FDA issues a new warning about aspiration across all GLP-1 weight loss drugs, doctor groups are giving new ...

The FDA updated GLP-1 drug labels to warn of the risk of patients breathing food into their lungs while under anesthesia for ...

has been “resolved” and removed from the FDA’s shortage list, see our prior blog “GLP-1 Drugs: FDA Removes Lilly’s Zepbound® and Mounjaro® (tirzepatide injection) from its Drug ...

News and talk of GLP-1 drugs are everywhere these days ... and what sometimes seems like an ever-growing list of other conditions the drugs could potentially treat. There are new headlines ...

In response to the FDA’s shortage decision, Hims & Hers is launching a new GLP-1 tracker, allowing patients to self-identify, provide ...

Poor bowel preparation also led to repeat colonoscopies for 18.9% of current GLP-1RA users, compared to 11.1% of controls ...

If you had come across the abbreviation GLP-1 a few years ago, chances are you’d have had no idea what it stood for. Intro to Greek lyric poetry? Low-level Great Lakes precipitation? A member of the ...